CALit2 UCI-Micro/Nanotechnology: The Human Impact John Stroh CEO Kevin McNerney COO. Nanospectra Biosciences

Transcription

1 CALit2 UCI-Micro/Nanotechnology: The Human Impact John Stroh CEO Kevin McNerney COO 1

2 Cancer Therapy Precise Thermal Destruction of Solid Tumors through Nanotechnology by the infusion of gold nanoshells (AuroLase ) Medical Device (Inert Particle, Laser) Broad Applications in Cancer Including Head & Neck, Prostate Brain (Primary and Mets), Lung Clinical Advantage - Precision Treat Irregular Shaped and Inoperable Tumors Preserve Critical Structures Unique Focal Therapy Adjunct Therapy Applications 2

3 AuroShell Particles for IV Administration Investigational (classified as a device by FDA) Interstitial Fiber Optic Probe FDA cleared 808 nm Laser 3

4 ~150 nm (classified as a device by FDA) AuroShell Particles for IV Administration 4

5 Targeted Precision Tumor-Specific Ablation Minimal Collateral Damage Clinical Challenges Addressed Inoperable Non-Resectable Non-Specific (e.g., Prostate) Adjunct to Current Treatments Radiation, Chemotherapy Enhancement 5

6 Residual Disease Surgical Margin Tumor Traditional Ablation Zones 6

7 Particles Flow with Blood Cleared from Blood by RES Blood Vessel Lining Normal Tissue Cells Blood Supply 7

8 tumor-specific accumulation: Tumor Blood Vessel Tumor Cells Blood Supply

9 Laser Nanoshells delivered absorb via percutaneous NIR, transduce optical to heat fiber Tumor Cells Blood Supply

10 Particle-Based Thermal Destruction Tumor Step 1: Particle Delivery by Infusion 10

11 Particle-Based Thermal Destruction Tumor Step 2: Energy Transduced by Particles 11

12 Particle-Based Thermal Destruction Step 2: Energy Transduced by Particles 12

13 Intravenous Particle Delivery Fiber Insertion in Control and Tumor Ablation of Tumor No Damage to Control MRI of Live Dog Brain During Therapy Healthy Tissue Laser Emission Area Applicators Tumor 35 C T ΔT ( C) Particle-Focused Ablation 5 C 13

14 Passive Accumulation, Single Dose % Surviving 100% 80% 60% 40% 20% AuroShell Treated (n=11) >90% Complete Response Sham Treatment (n=16) Untreated Control (n=17) 0% BALBc Mice, CT26 Cell Line Treatment at 5 mm diameter Euthanize 1 cm diameter Days after tumor treatment 1 Cancer Letters 209 (2004), p Proc. Of SPIE (2005), Vol. 5689, p

15 Sub-ablation temperatures improve efficacy of conventional therapies Radiation Chemotherapy Tumor centers become hypoxic (lives w/ little oxygen). Hypoxic tumor cells are tough, resistant to radiation and chemotherapy. Heating hypoxic tissue increases blood supply and oxygenation. Increased blood supply allows better access by chemo agents. Increased perfusion also increases oxygen level. Radiation produces singlet oxygen which poisons the cell. 15

16 Noted Healthcare Organizations MD Anderson Baylor University University of Texas Austin University of Texas Medical Branch Texas VA Cancer Treatment Centers of America Commercial Collaborations Sebacia (Duluth, GA) NanoComposix (San Diego, CA) Cytodiagnostics (Ontario, Canada) Sigma Aldrich (US) 16

17 Incidence (Global) Head & Neck (>650,000) human trial (FDA IDE)* Prostate (>910,000) human trial (outside US)* Brain (>225,000) $1.3MM NCI dog study* Melanoma (>180,000) (pig study) * ** Lung (>1.4MM) - CTCA** Colon (>1.2MM) Breast (>1.5MM) Pancreas (>200,000) Others * Clinical Trial Open ** Clinical Trial Planned Cancer Treatment Centers of America Source: American Cancer Society 17

18 Licenses from Rice University, U Texas - Medical Branch, U Texas -Austin 11 Issued US Patents 10 Licensed, 1 Owned 3 Pending Broad Protection in Cancer Ablation Imaging Synergy with Radiation Tumor Margin Identification 18

19 Management John Stroh: President, CEO & Director / Previously CEO of CryoCare & Neomatrix Kevin McNerney: COO/ Previously VP Ops of CryoCare, LifePoint & PMI MBA, BSME Glenn Goodrich PhD: VP Proc Dev & Chem / PhD Chem, Penn St, Post-Doc Rice Jon Schwartz PhD: Dir of Clinical Ops / PhD Biophysics, MD Anderson Cancer Ctr ~6 total employees Advisory Naomi Halas PhD: Co-Founder / Dir Laboratory for Nanophotonics, Rice Univ. Directors David Anderson: Chairman of the Board / Formerly CEO of MithraGen COO of Tanox Jennifer West PhD: Co-Founder / Prof. & Chair of Bioengr, Rice Dave Bristol: Officer and Director of HCF Enterprises, Inc. Patrick Pace MD: Managing Director at Citadel Securities 19

20 Particle based therapeutics have enormous potential in addressing the failures of traditional therapeutics Venture investors funded over $800M in early stage Nanotechnology companies in 2010 with 54% going to NanoMedicine companies Many clinicians see nanotechnology as the ideal solution for the detection and treatment of many diseases. As more Nanotechnology companies emerge from successful clinical trials the level of venture investing will continue to accelerate Nanospectra Biosciences 2010 Not to be copied, reproduced, electronically saved or distributed 20

21 Thank You 21